Health Condition 1: K754- Autoimmune hepatitis
Conditions
Interventions
Intervention1: Comparision of Mycophenolate mofetil and azathioprine in autoimmune hepatitis.: Mycophenolate mofetil and azathioprine will be compared in treatment naive autoimmune hepatitis.
MMF will
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Autoimmune hepatitis. Treatment naive. Subject who gives the consent to participate in the study.
Exclusion criteria
Exclusion criteria: Acute liver failure Platelets count less than 50000 TLC counts less than 3000 Existing liver disease, e.g. hepatitis B, C, PBC, PSC, alcohol intake, obesity Previous treatment exposure Lactating women and pregnancy HCC or other malignancy Allergic to specific medications A patient who is not willing to participate in the study or failed to provide the consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is reversing biochemical activity over a 24-week.Timepoint: Initially at two weeks, then at one-month intervals. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Study the adverse effects safety of MMF 2. Improvement in the quality of life index 3. Reversal of stage of fibrosis 4. No progression of fibrosis(by fibroscan)Timepoint: Initially, it was 2 weeks, then at a one-month interval. | — |
Countries
India
Contacts
Public ContactDr Babu Lal Meena
ILBS Delhi
Outcome results
None listed